Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04207320 · ClinicalTrials.gov registry record · NA
Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Severe Sickle Cell Disease
A NA study, sponsored by University of Chicago.
- Terminated
- Registry status
- NA
- Development phase
- 3
- Enrollment target
NCT04207320: Clinical Trial NA study, sponsored by University of Chicago.
NCT04207320 is a NA study that was terminated before completion, run by University of Chicago. The registered enrollment target is 3 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04207320, a NA study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- NA
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to develop a safe and curative stem cell transplant approach to treating sickle cell disease by assessing the safety of haploidentical hematopoietic stem cell transplantation using αβ+ T-cell depletion for children and adolescents with severe sickle cell disease (SCD).
Primary Outcome
Graft Function: efficacy is defined as stable donor engraftment (\>5% total nucleated cell DNA) and donor erythropoiesis that corrects the SCD hematologic phenotype (\<50% HbS in the peripheral blood). Organ Toxicity: grade III/IV irreversible end organ toxicity based on NCI grading Graft Versus Host disease: grade III/IV aGvHD or death within 100 days post- Hap-HSCT
Interventions
- DEVICE αβ+ T-cell depletion with Miltenyi CliniMACS system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-04-07 |
| Est. Completion | 2023-05-22 |
| Phase | NA |
Why NCT04207320 stopped before completion
NCT04207320 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which αβ+ T-cell depletion with Miltenyi CliniMACS system is the first listed.
NCT04207320 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04207320 about?
NCT04207320 is a clinical study titled "Haploidentical Hematopoietic Stem Cell Transplantation (HSCT) for Patients With Severe Sickle Cell Disease". The purpose of this study is to develop a safe and curative stem cell transplant approach to treating sickle cell disease by assessing the safety of haploidentical hematopoietic stem cell transplantation using αβ+ T-cell depletion for children and adolescents with severe sickle cell disease (SCD).
What is the current status of trial NCT04207320?
This trial is currently terminated. It is a NA study. The enrollment target is 3 participants. The study started on 2020-04-07. Estimated completion is 2023-05-22.
What interventions are being tested in trial NCT04207320?
The interventions under investigation include: αβ+ T-cell depletion with Miltenyi CliniMACS system (DEVICE).
Who is sponsoring clinical trial NCT04207320?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04207320's enrollment target sits among peer trials
3 1996th of 2000 higher than 4 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI